NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥10.4b

Last Updated

2021/04/11 09:12 UTC

Data Sources

Company Financials +

Executive Summary

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, develops and markets genetic engineering drugs in the People’s Republic of China and internationally. More Details


Snowflake Analysis

High growth potential with excellent balance sheet and pays a dividend.

Share Price & News

How has Beijing SL Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 002038 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 002038's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

4.9%

2038

2.5%

CN Biotechs

-1.1%

CN Market


1 Year Return

-16.2%

2038

39.3%

CN Biotechs

28.4%

CN Market

Return vs Industry: 002038 underperformed the CN Biotechs industry which returned 39.3% over the past year.

Return vs Market: 002038 underperformed the CN Market which returned 28.4% over the past year.


Shareholder returns

2038IndustryMarket
7 Day4.9%2.5%-1.1%
30 Day11.7%9.2%1.0%
90 Day4.0%0.3%-5.8%
1 Year-14.9%-16.2%39.8%39.3%30.4%28.4%
3 Year-59.0%-60.6%80.7%78.0%25.9%19.9%
5 Year-38.4%-41.6%61.2%58.2%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Beijing SL Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Beijing SL Pharmaceutical undervalued compared to its fair value and its price relative to the market?

29.26x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 002038 (CN¥10.15) is trading above our estimate of fair value (CN¥6.25)

Significantly Below Fair Value: 002038 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 002038 is good value based on its PE Ratio (29.3x) compared to the CN Biotechs industry average (55.8x).

PE vs Market: 002038 is good value based on its PE Ratio (29.3x) compared to the CN market (33.9x).


Price to Earnings Growth Ratio

PEG Ratio: 002038 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: 002038 is good value based on its PB Ratio (2.1x) compared to the CN Biotechs industry average (6x).


Future Growth

How is Beijing SL Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

35.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002038's forecast earnings growth (35.3% per year) is above the savings rate (3.3%).

Earnings vs Market: 002038's earnings (35.3% per year) are forecast to grow faster than the CN market (23.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002038's revenue (44.5% per year) is forecast to grow faster than the CN market (17.9% per year).

High Growth Revenue: 002038's revenue (44.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 002038's Return on Equity is forecast to be low in 3 years time (12.7%).


Past Performance

How has Beijing SL Pharmaceutical performed over the past 5 years?

-5.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 002038 has high quality earnings.

Growing Profit Margin: 002038's current net profit margins (31.8%) are higher than last year (23.9%).


Past Earnings Growth Analysis

Earnings Trend: 002038's earnings have declined by 5% per year over the past 5 years.

Accelerating Growth: 002038's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002038 had negative earnings growth (-26.5%) over the past year, making it difficult to compare to the Biotechs industry average (16.3%).


Return on Equity

High ROE: 002038's Return on Equity (7.2%) is considered low.


Financial Health

How is Beijing SL Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥312.2M).

Long Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥86.8M).


Debt to Equity History and Analysis

Debt Level: 002038's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 002038's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 002038's debt is well covered by operating cash flow (7025.1%).

Interest Coverage: 002038 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Beijing SL Pharmaceutical current dividend yield, its reliability and sustainability?

1.97%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 002038's dividend (1.97%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).

High Dividend: 002038's dividend (1.97%) is in the top 25% of dividend payers in the CN market (1.81%)


Stability and Growth of Payments

Stable Dividend: 002038's dividend payments have been volatile in the past 10 years.

Growing Dividend: 002038's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (57.7%), 002038's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average board tenure


CEO

Mingbo Xu (56 yo)

no data

Tenure

CN¥355,000

Compensation

Dr. Ming Bo Xu founded Beijing SL Pharmaceutical Co., Ltd. in December 1994 and serves as its Chairman, Chief Executive Officer, President and General Manager.


Board Members

Experienced Board: 002038's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Beijing SL Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beijing SL Pharmaceutical Co., Ltd.
  • Ticker: 2038
  • Exchange: SZSE
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥10.428b
  • Shares outstanding: 1.03b
  • Website: https://www.slpharm.com.cn

Number of Employees


Location

  • Beijing SL Pharmaceutical Co., Ltd.
  • No. 1 Building, Bitongyuan
  • No. 69 Fu shi Road
  • Beijing
  • 100049
  • China

Listings


Biography

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, develops and markets genetic engineering drugs in the People’s Republic of China and internationally. The company primarily provides its pr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:12
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.